Success Metrics

Clinical Success Rate
69.5%

Based on 41 completed trials

Completion Rate
69%(41/59)
Active Trials
19(21%)
Results Posted
117%(48 trials)
Terminated
18(20%)

Phase Distribution

Ph phase_1
38
42%
Ph early_phase_1
1
1%
Ph phase_2
37
41%
Ph phase_4
5
6%
Ph phase_3
7
8%

Phase Distribution

39

Early Stage

37

Mid Stage

12

Late Stage

Phase Distribution88 total trials
Early Phase 1First-in-human
1(1.1%)
Phase 1Safety & dosage
38(43.2%)
Phase 2Efficacy & side effects
37(42.0%)
Phase 3Large-scale testing
7(8.0%)
Phase 4Post-market surveillance
5(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.2%

41 of 67 finished

Non-Completion Rate

38.8%

26 ended early

Currently Active

19

trials recruiting

Total Trials

90

all time

Status Distribution
Active(19)
Completed(41)
Terminated(26)
Other(4)

Detailed Status

Completed41
Terminated18
Active, not recruiting15
Withdrawn8
Recruiting4
unknown4

Development Timeline

Analytics

Development Status

Total Trials
90
Active
19
Success Rate
69.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.1%)
Phase 138 (43.2%)
Phase 237 (42.0%)
Phase 37 (8.0%)
Phase 45 (5.7%)

Trials by Status

recruiting44%
terminated1820%
completed4146%
unknown44%
withdrawn89%
active_not_recruiting1517%

Recent Activity

19 active trials
Showing 5 of 90
terminatedphase_1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700
active_not_recruitingphase_1

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042
terminatedphase_4

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

NCT03173092
active_not_recruitingphase_2

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03763162
active_not_recruitingphase_1

Ixazomib + Pomalidomide + Dexamethasone In MM

NCT04094961
View all 90 trials

Clinical Trials (90)

Showing 20 of 90 trialsScroll for more
NCT03547700Phase 1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Terminated
NCT02343042Phase 1

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Active Not Recruiting
NCT03173092Phase 4

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Terminated
NCT03763162Phase 2

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Active Not Recruiting
NCT04094961Phase 1

Ixazomib + Pomalidomide + Dexamethasone In MM

Active Not Recruiting
NCT03283917Phase 1

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Active Not Recruiting
NCT03587662Phase 2

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Active Not Recruiting
NCT05722405Phase 4

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Recruiting
NCT04068597Phase 1

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Recruiting
NCT04009109Phase 2

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active Not Recruiting
NCT02461888Phase 2

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Completed
NCT03618537Phase 2

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Active Not Recruiting
NCT02253316Phase 2

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Active Not Recruiting
NCT03590652Phase 2

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Terminated
NCT02412228Phase 2

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

Completed
NCT01659658Phase 3

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Terminated
NCT02916771Phase 2

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Completed
NCT04052880Phase 2

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Active Not Recruiting
NCT05451771Phase 1

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Recruiting
NCT02765854Phase 2

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Completed

Drug Details

Intervention Type
DRUG
Total Trials
90